SAN FRANCISCO--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic ...

Please provide your email address to receive an email when new articles are posted on . Among systemic rheumatic diseases, the risk for opportunistic infection is highest among patients with ...

PF1801 is a novel long-acting glucagon-like peptide-1 receptor agonist. The Food and Drug Administration (FDA) has granted Orphan Drug designation to PF1801 for the treatment of polymyositis.

Idiopathic inflammatory myopathies, known collectively as myositis, are chronic diseases that cause disability, mainly from muscle weakness, despite the use of immunosuppressive therapies. An improved ...

Managing myositis and its systemic complications represents a challenge to the clinicians providing care as patients often have severe muscle weakness, notable skin rashes and life-threatening organ ...

LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the polymyositis market. The report includes a detailed analysis of the pipeline molecules under investigation ...